American Journal of Medicine Studies
ISSN (Print): 2333-8881 ISSN (Online): 2333-889X Website: Editor-in-chief: Apply for this position
Open Access
Journal Browser
American Journal of Medicine Studies. 2021, 9(1), 1-3
DOI: 10.12691/ajms-9-1-1
Open AccessCase Report

Clinic Value Analysis of Combined Detection of White Blood Cells and T-cell Subgroups in a Patient with SARS-CoV-2 Infection

Jianwei Zhou1, , Yu Li1, 2, Cui Kong3, Yizhao Li4, Qinhua Zhang5, Shuheng Hu1 and Xinke Chen1

1Medical Laboratory, Affiliated Hospital of Jining Medical University, Jining, China

2Medical College, Jining Medical University, Jining, China

3Nursing Department, Affiliated Hospital of Jining Medical University, Jining, China

4Rehabilitation Department, Fangan Rehabilitation Hospital of Jinan City, Jinan, China

5Neurology Department, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China

Pub. Date: January 28, 2021

Cite this paper:
Jianwei Zhou, Yu Li, Cui Kong, Yizhao Li, Qinhua Zhang, Shuheng Hu and Xinke Chen. Clinic Value Analysis of Combined Detection of White Blood Cells and T-cell Subgroups in a Patient with SARS-CoV-2 Infection. American Journal of Medicine Studies. 2021; 9(1):1-3. doi: 10.12691/ajms-9-1-1


To analyze and assess the changes of peripheral blood cells of a patient with SARS-CoV-2 infection, we collected and retrospectively analyzed the white blood cells, T-cell subgroups and interleukin 6 (IL-6) of a patient with COVID-19. Compared to the corresponding normal range, the percent of eosinophiles (ESO%) and count of EOS decreased; the percent of T-cell subgroup with double negative for cluster of differentiation 4 and 8 (CD4-CD8- T%) increased. The concentration of IL-6 was 21.5 pg/ml, which far exceeded the normal range (0-3.4 pg/ml). These results indicated that some indices of peripheral blood cells could be taken as reference parameters to assess the infection or severity of SARS-CoV-2.

COVID-19 IL-6 Lymphocyte SARS-CoV-2 T-cell subgroup

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit


[1]  WHO. WHO Coronavirus Disease (COVID-19) Dashboard - Data last updated: 2021/1/23, 4:57pm CET. 2021,
[2]  Zhang JJ, Dong X, Cao YY, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy, 2020, 75(7): 1730-1741.
[3]  Chen L, Liu .G, Liu W,et al. Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia. Zhonghua Jie He He Hu Xi Za Zhi, 2020, 43(0):E005.
[4]  Li YX, Wu W, Yang T, et al. Characteristics of peripheral blood leukocyte differential counts in patients with COVID-19. Zhonghua Nei Ke Za Zhi, 2020. 59(5): 372-374.
[5]  Xu Z, Shi L, Wang Y, Huang L, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med, 2020, 8(4): 420-422.
[6]  Huang Y, Tu M, Wang S, et al. Clinical characteristics of laboratory confirmed positive cases of SARS-CoV-2 infection in Wuhan, China: A retrospective single center analysis. Travel Med Infect Dis, 2020, 36: 101606.
[7]  Wang L, Gao YH, Lou LL, et al. The clinical dynamics of 18 cases of COVID-19 outside of Wuhan, China. Eur Respir J, 2020, 55(4): 2000398.
[8]  Zhang G, Zhang J, Wang B, et al. Analysis of clinical characteristics and laboratory findings of 95 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a retrospective analysis. Respir Res, 2020, 21(1): 74.
[9]  Shi Y, Wang Y, Shao C, et al. COVID-19 infection: the perspectives on immune responses. Cell Death Differ, 2020, 27(5): 1451-1454.
[10]  Chu J, Yang N, Wei Y, et al. Clinical Characteristics of 54 Medical Staff With COVID-19: A Retrospective Study in a Single Center in Wuhan, China. J Med Virol, 2020, 92(7): 807-813.
[11]  Li LQ, Huang T, Wang YQ, et al. COVID-19 patients' clinical characteristics, discharge rate, and fatality rate of meta-analysis. J Med Virol, 2020, 92(6):577-583.
[12]  Tan L, Wang Q, Zhang D, et al. Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study. Sig Transduct Target Ther, 2020, 5(1): 33.
[13]  Liu WJ, Zhao M, Liu K, et al. T-cell immunity of SARS-CoV: implications for vaccine development against MERS-CoV. Antiviral Res, 2017, 137: 82-92.
[14]  Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 2020, 395(10223): 497-506.
[15]  Zheng HY, Zhang M, Yang CX, et al. Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients. Cell Mol Immunol, 2020, 17(5): 541-543.
[16]  Wan SX, Xiang Y, Fang W, et al. Clinical features and treatment of COVID-19 patients in northeast Chongqing. J Med Virol, 2020, 2(7): 797-806.
[17]  Wan S, Yi Q, Fan S, et al. Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP). 2020, Medrxiv.
[18]  Ulhaq ZS, Soraya GV. Interleukin-6 as a potential biomarker of COVID-19 progression. Med Mal Infect, 2020, 50(4):382-383.
[19]  Liu J, Li S, Liu J, et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. EBioMedicine, 2020, 55:102763.